Summary
Abuse of prescription opioids continues to be a serious public health concern, with as many as 12.5 million individuals aged 12 or older reporting nonmedical use of prescription pain relievers in 2015. Oxycodone ARIR is the first abuse-deterrent formulation of an IR opioid approved by the Food and Drug Administration and was developed to have similar relative bioavailability to IR oxycodone. Patients can be converted from IR oxycodone to the same dose and dosing regimen of Oxycodone ARIR. It has been demonstrated that when crushed and taken intranasally, Oxycodone ARIR has a 47% and a 23% reduction in mean maximum drug liking compared with crushed intranasal IR oxycodone and intact oral Oxycodone ARIR, respectively.
Register to download
Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone ARIR
You may also be interested in:
Poster
A Blueprint to Success: Onboarding a Medical Writer
Onboarding is the process of welcoming new employees into an organization and providing them with the tools, resources, and knowledge to become…
Case Study
PRA Teamwork Demonstrates Vision
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project…
Fact Sheet
CSF Sampling
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…